|
DVAX | Dynavax Technologies Corp |
|
|
DVAX | Dynavax Technologies Corp |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.27 |
| Leverage | 43.57% |
| Market Cap | $ 2.0B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -43.6m |
| Margin | -13.25% |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.